We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current CHGCF market cap is 48.92B. The company's latest EPS is JPY 197.9374 and P/E is 0.15.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 686.18B | 787.01B | 999.76B | 1.26T | 1.14T |
| Operating Income | 210.6B | 301.23B | 419.36B | 531.18B | 439.17B |
| Net Income | 157.56B | 214.73B | 303B | 374.43B | 325.47B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 1.06T | 1.24T | 1.54T | 1.87T | 1.93T |
| Total Liabilities | 204.93B | 255.5B | 350.68B | 445.37B | 306.97B |
| Total Equity | 853.99B | 980B | 1.19T | 1.42T | 1.63T |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 206.64B | 205.04B | 279.63B | 244.11B | 409.93B |
| Investing | -81.74B | -98.31B | -118.93B | -145.99B | -37.29B |
| Financing | -66.87B | -99.5B | -107.41B | -145.64B | -139.33B |
| Market Cap | 48.92B |
| Price to Earnings Ratio | 0.15 |
| Price to Sales Ratio | 0.04 |
| Price to Cash Ratio | 0.11 |
| Price to Book Ratio | 0.03 |
| Dividend Yield | - |
| Shares Outstanding | 1.64B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 3.44k |
| 52 Week Change | 0.11% |
| 52 Week High | 43.722 |
| 52 Week Low | 26.61 |
| Spread (Intraday) | 2.9 (9.1%) |
| Company Name | Chugai Pharmaceutical Ltd (PK) |
| Address |
2-1-1 muromachi-nihonbashi chuo, tokyo 103-8324 |
| Website | https://www.chugai-pharm.co.jp |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
